NASDAQ · MCRB
Seres Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for MCRB: Nov 4, 2026
Seres Therapeutics, Inc. Common Stock is estimated to report earnings on 11/04/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.34. The reported EPS for the same quarter last year was $0.94.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.34 | $-1.34 | $-1.34 | 1 |
| Dec 2026 | $-1.37 | $-1.37 | $-1.37 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · MarketBeat · Zacks · Fintel- RTTNews · Aug 19, 1:45 PM EDTSeres Therapeutics Swings To Q2 Profit; SER-155 Data Support Further Development In IrEC(RTTNews) – Seres Therapeutics, Inc. (MCRB), a clinical-stage biotechnology company, recently reported financial results for the second quarter ended June 30, 2026, and provided business updates.
- MarketBeat · Jul 10, 2:02 PM EDTSeres Therapeutics’ SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity StudySeres Therapeutics (NASDAQ:MCRB) reported results from an investigator-sponsored study of SER-155 in immune checkpoint inhibitor-related enterocolitis, or irEC, saying the data support further evaluation of the live biotherapeutic as a potential non-immunosuppressive treatment op
- Zacks · Dec 29, 10:15 AM EST3 Beaten-Down Biotech Stocks to Buy for a 2026 TurnaroundBeaten-down biotech stocks like ALT, IBRX and MCRB are eyeing a 2026 rebound as FDA alignment, pipeline progress and approvals fuel optimism.
- Fintel · Dec 5, 12:39 PM ESTSeres Therapeutics (MCRB) Price Target Increased by 31.25% to 21.42The average one-year price target for Seres Therapeutics (NasdaqGS:MCRB) has been revised to $21.42 / share. This is an increase of 31.25% from the prior estimate of $16.32 dated November 14, 2025. The price target is an average of many targets provided by ana
- The Motley Fool · Nov 5, 8:12 PM ESTSeres (MCRB) Q3 2025 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Sep 23, 7:44 AM EDTSeres Gets Constructive Feedback From FDA On Phase 2 Study Protocol For SER-155; To Cut Workforce(RTTNews) – Seres Therapeutics (MCRB) announced receipt of additional constructive feedback from the FDA on the Phase 2 study protocol for the company's lead program, SER-155, for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell tra
- Zacks · Sep 9, 12:00 PM EDTAll You Need to Know About Seres Therapeutics (MCRB) Rating Upgrade to BuySeres Therapeutics (MCRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- RTTNews · Sep 9, 1:11 AM EDTBiotech Stocks Surge After Hours: CAPR, TMDX Lead Gains Amid Trial Updates And Earnings Momentum(RTTNews) – Several biotech and medical technology stocks posted notable gains in after-hours trading on Monday, with momentum driven by a mix of earnings optimism, clinical trial progress, and speculative positioning. While some names rallied on fresh developments, like TransMed
- Zacks · Aug 28, 9:55 AM EDTSeres Therapeutics (MCRB)'s Technical Outlook is Bright After Key Golden CrossShould investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
- The Motley Fool · Aug 6, 9:23 PM EDTSeres (MCRB) Q2 Loss Narrows 34%GAAP EPS loss of $2.27 in Q2 2025 was narrower than the expected $2.49.
- RTTNews · Jul 22, 8:19 AM EDTSeres Therapeutics CEO Eric Shaff To Resign, Thomas DesRosier And Marella Thorell To Be Co-CEOs(RTTNews) – Seres Therapeutics, Inc. (MCRB), Tuesday announced that Chief Executive Officer Eric Shaff will resign from the position, effective July 31, 2025, to pursue a new professional opportunity.
- Quiver Quantitative · Jul 22, 7:13 AM EDTSeres Therapeutics to Host Conference Call on August 6, 2025, to Discuss Q2 Financial Results and Business UpdatesSeres Therapeutics will discuss Q2 2025 results and updates on August 6, 2025. Access details provided.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Seres Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.